Clare B. Billing

发表

Efficacy of Varenicline , an 4 2 Nicotinic Acetylcholine Receptor Partial Agonist , vs Placebo or Sustained-Release Bupropion for Smoking Cessation A Randomized Controlled Trial

Jason Gong, Douglas E. Jorenby, N. Rigotti, 2006 .

Development of a straightforward and sensitive scale for MCI and early AD clinical trials

Kaori Ito, R. Anziano, Kaori Ito, 2015, Alzheimer's & Dementia.

Varenicline, an α4β2 Nicotinic Acetylcholine Receptor Partial Agonist, vs Sustained-Release Bupropion and Placebo for Smoking Cessation: A Randomized Controlled Trial

David Gonzales, Jason Gong, Stephen I. Rennard, 2006 .

Efficacy and Safety of Oral Dofetilide in Converting to and Maintaining Sinus Rhythm in Patients With Chronic Atrial Fibrillation or Atrial Flutter: The Symptomatic Atrial Fibrillation Investigative Research on Dofetilide (SAFIRE-D) Study

M. Brodsky, G. Feld, Steven N. Singh, 2000, Circulation.

Efficacy of Varenicline, an 42 Nicotinic Acetylcholine Receptor Partial Agonist, vs Placebo or Sustained-Release Bupropion for Smoking Cessation A Randomized Controlled Trial

Jason Gong, Douglas E. Jorenby, N. Rigotti, 2006 .

Preliminary population pharmacokinetic modeling of PF-04360365, a humanized anti-amyloid monoclonal antibody, in patients with mild-to-moderate Alzheimer's disease

B. Corrigan, Qinying Zhao, T. Nicholas, 2009, Alzheimer's & Dementia.

Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial.

S. Tonstad, P. Hajek, P. Tønnesen, 2006, JAMA.

Comment and Reply: A double-blind study evaluating the long-term safety of varenicline for smoking cessation

J. Spangler, C. Billing, Clare B. Billing, 2008, Current medical research and opinion.

Pharmacological Characterization of a Novel Neuroactive Steroid Prodrug, NTS-104, and Its Neuroprotective Activity in Experimental Stroke Models

M. Chopp, T. Verdoorn, Zhenggang Zhang, 2022, Stroke.

Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial.

S. Rennard, D. Gonzales, C. Oncken, 2006, JAMA.

Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial.

N. Rigotti, D. Jorenby, J. T. Hays, 2006, JAMA.

Varenicline versus transdermal nicotine patch for smoking cessation: results from a randomised open-label trial

J. Britton, C. Oncken, C. Billing, 2008, Thorax.

A randomized, placebo-controlled trial of varenicline, a selective alpha4beta2 nicotinic acetylcholine receptor partial agonist, as a new therapy for smoking cessation in Asian smokers.

Hong-Jun Cho, C. Billing, Clare B. Billing, 2007, Clinical therapeutics.

Efficacy of Varenicline, an (cid:1) 4 (cid:2) 2 Nicotinic Acetylcholine Receptor Partial Agonist, vs Placebo or Sustained-Release Bupropion for Smoking Cessation A Randomized Controlled Trial

N. Rigotti, D. Jorenby, C. Billing, 2006 .

Safety and Pharmacology of a Single Intravenous Dose of Ponezumab in Subjects With Mild-to-Moderate Alzheimer Disease: A Phase I, Randomized, Placebo-Controlled, Double-Blind, Dose-Escalation Study

Qinying Zhao, M. Borrie, K. Bales, 2013, Clinical neuropharmacology.

The efficacy and safety of varenicline for smoking cessation using a flexible dosing strategy in adult smokers: a randomized controlled trial

D. Jorenby, F. Leone, R. Niaura, 2008, Current medical research and opinion.